(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of 36.33% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.82%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Syndax Pharmaceuticals's revenue in 2026 is $252,251,000.On average, 15 Wall Street analysts forecast SNDX's revenue for 2026 to be $28,961,723,902, with the lowest SNDX revenue forecast at $26,568,561,998, and the highest SNDX revenue forecast at $31,691,535,821. On average, 14 Wall Street analysts forecast SNDX's revenue for 2027 to be $40,848,059,020, with the lowest SNDX revenue forecast at $34,082,018,814, and the highest SNDX revenue forecast at $48,103,447,257.
In 2028, SNDX is forecast to generate $58,028,818,366 in revenue, with the lowest revenue forecast at $43,755,572,140 and the highest revenue forecast at $76,415,981,345.